Conversational AI startup Sierra secures $175m funding
Sierra, a US-based conversational AI startup, has secured $175m in a funding round, catapulting the company’s valuation to $4.5bn.
Related Articles
Aetna, Optum to settle ‘dummy code’ class-action case
Aetna and OptumHealth agreed to settle a long-running class-action lawsuit over their administration of employee health benefits.
Insulet raises annual revenue forecast on strong demand for insulin pumps
Insulet raised its annual revenue growth forecast on Thursday, banking on strong demand for its wearable insulin pumps.
Immunosuppressive agents or intravenous immunoglobulin in addition to glucocorticoids in the treatment of Susac syndrome: a French national cohort study
The combination of glucocorticoids with immunosuppressive agents or intravenous immunoglobulin did not appear to reduce the risk of Susac syndrome relapse compared with glucocorticoids alone.…
Patient Information: Chronic Pruritus
This JAMA Patient Page describes the types of chronic pruritus and its symptoms and signs and treatment strategies.
Neurodevelopment Following Prenatal Exposure to Maternal SARS-CoV-2 Infection
This cohort study examines whether there are differences in neurodevelopmental outcomes during the first 2 years of life among children who were exposed and unexposed…
Healthcare: What Could Change Under New Trump Administration?
The Affordable Care Act may not be dismantled, but Americans could see lower subsidies, say experts. Other changes may apply to prescription drug price caps…
Sleep Disorders
There are more than 90 recognized sleep disorders, many of which impair sleep and daytime function and adversely impact heath, well-being, and chronic disease risk.…
‘I have 100 scarecrows and can’t protect my crops from geese’
Marty Hay says the geese can go through an acre of crops overnight, which can cost up to £700 to grow.
Obesity is a disease. Weight loss drugs are just one way to treat it, says this expert in bariatric surgery (podcast)
Cleveland Clinic expert discusses treatment options for obesity including weight loss drugs and bariatric surgery.
Xanax maker Viatris beats quarterly estimates on demand for new generic drugs
Drugmaker Viatris beat Wall Street estimates for third-quarter profit and revenue on Thursday, helped by strong demand for its new generic asthma and ADHD drugs,…